omeprazole has been researched along with posaconazole in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Krishna, G; Ma, L; McLeod, J; Medlock, MM; Moton, A | 1 |
| Alffenaar, JW; Kosterink, JG; Uges, DR; van Assen, S; van der Werf, TS | 1 |
2 review(s) available for omeprazole and posaconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 trial(s) available for omeprazole and posaconazole
| Article | Year |
|---|---|
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Antifungal Agents; Area Under Curve; Black or African American; Carbonated Beverages; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Eating; Fasting; Female; Food-Drug Interactions; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Middle Aged; Omeprazole; Suspensions; Triazoles; White People; Young Adult | 2009 |
3 other study(ies) available for omeprazole and posaconazole
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Omeprazole significantly reduces posaconazole serum trough level.
Topics: Drug Interactions; Humans; Omeprazole; Serum; Triazoles | 2009 |